Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) announces an exclusive license, supply and distribution agreement with Melinta Therapeutics (Melinta), for Melinta’s intravenous and oral formulations of Baxdela
London, 28 February 2019 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) announces an exclusive license, supply and distribution agreement with Melinta Therapeutics (Melinta), for Melinta’s intravenous and oral formulations of Baxdela™ (delafloxacin) across all its MENA markets. In addition, Hikma has the right of first negotiation for all other products in Melinta’s portfolio and pipeline in the region.
Baxdela™ is a novel antibiotic product used for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI). Baxdela™ is a fluoroquinolone with demonstrated efficacy against both gram-positive and gram-negative pathogens, including MRSA (methicillin-resistant Staphylococcus aureus). Baxdela™ was approved by the US Food and Drug Administration (FDA) in 2017.
Hikma is a leading provider of antibiotics in the MENA region, offering a wide range of products to doctors and pharmacists. As Antimicrobial Resistance (AMR) continues to pose treatment challenges for healthcare professionals, offering this new, innovative product in the region will arm them with new ways to combat this growing threat.
Mazen Darwazah, Executive Vice Chairman and President of MENA said, “We are very pleased to establish a partnership with Melinta and to be able to bring this innovative product to the region. As the challenge of AMR grows, we have an important role to play in helping to equip doctors here in MENA with the latest and most innovative developments.”
-- ENDS --
Enquiries
Hikma Pharmaceuticals PLC
|
Susan Ringdal EVP, Strategic Planning and Global Affairs |
+44 (0)20 7399 2760/ +44 7776 477050 |
|
Lucinda Baker Deputy Director of Investor Relations |
+44 (0)20 7399 2765/ +44 7818 060211 |
|
Virginia Spring Senior Investor Relations Manager |
+44 (0)20 3892 4389/ +44 7973 679502 |
FTI Consulting
Ben Atwell/Andrew Ward
About Hikma
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we’re a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people’s lives. We’re committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.
Carissa Gilbert
Senior Consultant | Strategic Communications
FTI Consulting
+44 (0)20 3727 1861
carissa.gilbert@fticonsulting.
200 Aldersgate | Aldersgate Street
London EC1A 4HD
